480 ARSENAL WAY, SUITE 100, WATERTOWN, MA
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Termination of OncoSignature Diagnostic Agreement with Akoya Biosciences
Investor Presentation
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data
Financial Results, Press Release
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload